We went on to test ACBI2 in vivo and observed dose-dependent SMARCA2 degradation in NCI-H1568 and A549 engrafted tumour bearing mice following short-term treatment (Fig. 4e, f). The gene discussed is SMARCA2; the disease is neoplasm.